Drug Information

Drug General Information
Drug ID
D05UQD
Former ID
DCL000188
Drug Name
Omapatrilat
Synonyms
BMS-186716; Omapatrilat (JAN/USAN/INN); (4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
Drug Type
Small molecular drug
Indication Hypertension [ICD9: 401; ICD10:I10-I16] Terminated [526007]
Company
Bristol-Myers Squibb
Structure
Download
2D MOL

3D MOL
Formula
C19H24N2O4S2
Canonical SMILES
C1CC(N2C(C1)SCCC(C2=O)NC(=O)C(CC3=CC=CC=C3)S)C(=O)O
InChI
1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1
InChIKey
LVRLSYPNFFBYCZ-VGWMRTNUSA-N
CAS Number
CAS 167305-00-2
PubChem Compound ID
656629
PubChem Substance ID
7849032, 7980221, 9268072, 12014939, 14879584, 14879585, 50280790, 53787321, 57408363, 103218648, 103966597, 113527924, 128548226, 134338857, 137246265, 137271248, 142473425, 179150045, 198936670, 226499350
Target and Pathway
Target(s) Neutral endopeptidase Target Info Modulator [526007]
Angiotensin-converting enzyme Target Info Modulator [526007]
KEGG Pathway Renin-angiotensin system
Hematopoietic cell lineage
Protein digestion and absorption
Alzheimer's diseasehsa04614:Renin-angiotensin system
Chagas disease (American trypanosomiasis)
Hypertrophic cardiomyopathy (HCM)
NetPath Pathway EGFR1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
PathWhiz Pathway Angiotensin Metabolism
Reactome Metabolism of Angiotensinogen to AngiotensinsR-HSA-2022377:Metabolism of Angiotensinogen to Angiotensins
WikiPathways Metabolism of Angiotensinogen to Angiotensins
Primary Focal Segmental Glomerulosclerosis FSGS
Alzheimers DiseaseWP554:ACE Inhibitor Pathway
References
Ref 526007Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr;155(2):291-5.
Ref 526007Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr;155(2):291-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.